Clinical Trial Update: Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Sunitinib in patients with recurrent paraganglioma and pheochromocytoma; the study is completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Paraganglioma, Pheochromocytoma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-17